Stockreport

NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer [Yahoo! Finance]

Nanobiotix S.A. - ADSs  (NBTX) 
PDF PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pion [Read more]